ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,514Medicare Part D Prescriptions Filled, Including Refills

Rank: 158 out of 1006

$528K Total Retail Price of All Prescriptions

Rank: 205 out of 1006

243 Patients Receiving at Least One Drug in Part D
84%Patients 65 Years and Older
78% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Connecticut
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 243 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

16% of this provider’s 243 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

1% of this provider’s 7,407 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

32% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$62 was the average price of a prescription from this provider, compared to $71 among peers.

Prescriptions per Patient

35 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
AMLODIPINE BESYLATE 395 347 1 4
SIMVASTATIN 372 303 2 1
ATORVASTATIN CALCIUM 269 242 3 5
OMEPRAZOLE 233 193 4 9
METFORMIN HCL 228 195 5 10
LISINOPRIL 216 184 6 3
WARFARIN SODIUM 192 190 7 8
METOPROLOL TARTRATE 169 163 8 7
METFORMIN HCL ER 167 138 9 56
LEVOTHYROXINE SODIUM 165 136 10 2
FUROSEMIDE 152 147 11 6
GLIMEPIRIDE 144 116 12 50
HYDROCODONE-ACETAMINOPHEN 137 108 S3 13 25
JANUVIA 128 108 14 49
DONEPEZIL HCL 124 124 15 17
HYDROCHLOROTHIAZIDE 118 112 16 11
LIPITOR 110 95 17 47
MIRTAZAPINE 110 100 17 26
ZOLPIDEM TARTRATE 107 89 19 14
OXYCODONE-ACETAMINOPHEN 107 57 S2 19 57
NEXIUM 105 88 21 28
LOSARTAN POTASSIUM 99 75 22 22
VYTORIN 89 43 23 145
ALENDRONATE SODIUM 88 83 24 29
DIOVAN 86 86 25 16
SYNTHROID 85 57 26 42
TAMSULOSIN HCL 84 84 27 23
PRAVASTATIN SODIUM 81 74 28 15
RISPERIDONE 80 80 29 40
BENICAR HCT 76 73 30 120
PROAIR HFA 74 56 31 64
ADVAIR DISKUS 72 68 32 37
METOPROLOL SUCCINATE 70 53 33 12
LOSARTAN-HYDROCHLOROTHIAZIDE 67 67 34 81
ACTOS 67 61 34 89
NAMENDA 66 66 36 34
LISINOPRIL-HYDROCHLOROTHIAZIDE 65 53 37 38
ZETIA 64 46 38 51
BENICAR 63 46 39 78
CLOPIDOGREL 63 51 39 46
SERTRALINE HCL 60 60 41 19
ACETAMINOPHEN-CODEINE 56 48 S3 42 139
TRAZODONE HCL 56 56 42 21
CRESTOR 55 40 44 18
GABAPENTIN 53 52 45 20
MELOXICAM 53 29 45 67
PREDNISONE 53 49 45 33
ESCITALOPRAM OXALATE 52 52 48 27
CITALOPRAM HBR 50 44 49 24
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 31, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.